Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells
- 26 October 2009
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Drug Discovery
- Vol. 8 (12), 969-981
- https://doi.org/10.1038/nrd3031
Abstract
No abstract availableKeywords
This publication has 137 references indexed in Scilit:
- Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritisExperimental and Molecular Pathology, 2009
- Genome-wide Mapping of HATs and HDACs Reveals Distinct Functions in Active and Inactive GenesCell, 2009
- Human T Regulatory Cell Therapy: Take a Billion or So and Call Me in the MorningImmunity, 2009
- A Role of DNA-PK for the Metabolic Gene Regulation in Response to InsulinCell, 2009
- Keeping things quiet: Roles of NuRD and Sin3 co-repressor complexes during mammalian developmentThe International Journal of Biochemistry & Cell Biology, 2009
- The many roles of histone deacetylases in development and physiology: implications for disease and therapyNature Reviews Genetics, 2009
- The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and menNature Reviews Molecular Cell Biology, 2008
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Therapeutic potential of resveratrol: the in vivo evidenceNature Reviews Drug Discovery, 2006
- Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancerNature Reviews Cancer, 2006